+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 8 Actively Recruiting clinical trials

S

Actively Recruiting

Researchers are investigating new treatments for neovascular age-related macular degeneration NVAMD, a condition that affects vision. This study aims to learn if a medicine called tiespectus also known as MK-8748 or EYE201 can treat NVAMD as well as the standard treatment called aflibercept. The trial is a pivotal Phase 23 study that compares these treatments in people newly diagnosed with NVAMD. Participants are randomly assigned to one of three groups one group receives a low dose of tiespectus, another receives a high dose of tiespectus, and the third group receives aflibercept. Those in the tiespectus groups get three initial injections every 4 weeks, then continue injections every 8 weeks until week 48, followed by treatments at intervals based on their individual response up to week 92. The aflibercept group receives three initial injections followed by injections every 8 weeks until week 92. During the study, participants are regularly assessed for changes in their best-corrected visual acuity using ETDRS letters from baseline to one year. Other evaluations include eye imaging to measure retinal thickness and monitoring for any adverse events up to approximately 96 weeks. The study lasts over one year with ongoing visits to track treatment response and safety.

Age: 50Years +All GendersPhase 2Phase 3
71 locations
E

Actively Recruiting

Researchers are evaluating the effectiveness of Vagus Nerve Stimulation VNS Therapy as an additional treatment for people with treatment-resistant depression. The study compares active VNS treatment with a no stimulation control over a 12-month period to see if VNS can reduce depressive symptoms measured by several depression scales. This is a prospective, multi-center, randomized, controlled, and blinded trial involving subjects who have VNS devices implanted. Participants receive the VNS implant, and after at least two weeks, they are randomized to either have the device activated or not activated for the first 12 months. Those in the control group can receive stimulation after 12 months. After the initial 12-month randomized phase, all participants transition into an open-label, long-term study lasting about 5 years. New subjects may also enroll directly into this extension phase. During the trial, participants are assessed regularly using multiple depression rating scales and questionnaires to monitor changes in symptoms, response times, remission, and adverse events. Safety and quality of life measures are also tracked. The study includes thorough monitoring of depressive symptoms and overall functioning for up to 12 months post-randomization, followed by long-term observation for several years.

Age: 18Years +All GendersPhase Not Applicable
101 locations
S

Actively Recruiting

Researchers are evaluating the use of AlloMend Acellular Dermal Matrix allograft in women who have undergone pre-pectoral breast reconstruction surgery after a single or double mastectomy. This retrospective study aims to describe and assess the effectiveness and safety of AlloMend in this surgical context, focusing on its use in stabilizing breast implants and minimizing implant loss during reconstruction. AlloMend is a sterile, human-derived acellular dermal matrix made from donated full-thickness skin that has been processed to remove cellular layers. It is used alongside breast implants or tissue expanders in either one-stage direct-to-implant or two-stage expander-to-implant breast reconstruction procedures. The allograft supports the implant position and is designed to integrate into the surgical site, promoting blood vessel growth and reducing inflammation or rejection. Participants in this study have completed or will complete follow-up evaluations at 2 weeks, 6 weeks, 3 months, and 6 months after surgery. Researchers collect descriptive data and assess physical function and quality of life up to six months post-operation. The study involves reviewing medical records retrospectively to evaluate outcomes and monitor safety over this period.

Age: 18Years +FEMALE
1 location
L

Actively Recruiting

Researchers are assessing the long-term safety and tolerability of the Port Delivery System with ranibizumab PDS in people with neovascular age-related macular degeneration nAMD who have completed previous related studies or certain visits within those studies. The trial includes two sub-studies to evaluate specific aspects one tests the effectiveness of transscleral photocoagulation to reduce vitreous hemorrhages after PDS implantation, and the other assesses the safety of re-implantation with an updated PDS device. Participants receive the PDS implant with ranibizumab at a concentration of 100 mgmL, administered through refill-exchange procedures at set intervals varying by previous study involvement, typically every 24 weeks with some switching to every 12 weeks later in the trial. The sub-studies involve additional treatments such as laser therapy or re-implantation and follow-up for up to 72 weeks. Treatment schedules and monitoring differ depending on enrollment cohorts and prior participation. Throughout the study, participants undergo regular assessments including eye exams, imaging, and monitoring for adverse events related to the PDS implant and ranibizumab treatment. The study tracks vision changes, ocular health, device safety, and any complications over periods up to 240 weeks or longer if regulatory approval is pending. Participants adherence to visit schedules and safety measures are closely observed as part of the trials long-term evaluation.

Age: 50Years +All GendersPhase 3
165 locations
S

Actively Recruiting

Researchers are studying patients with high-risk smoldering multiple myeloma to compare how well lenalidomide and dexamethasone work with or without daratumumab in treating this condition. The trial aims to assess overall survival, progression-free survival, response rates, safety, and quality of life among participants, while also exploring treatment adherence and disease markers over time. Participants are randomly assigned to one of two groups. One group receives daratumumab intravenously on a set schedule along with oral lenalidomide daily and oral dexamethasone on specified days in 28-day treatment cycles for up to 24 courses. The other group receives only oral lenalidomide and dexamethasone on a similar 28-day cycle schedule for the same duration, unless disease progression or unacceptable side effects occur. Throughout the study, participants will undergo regular assessments including blood tests, bone marrow biopsies, imaging scans, and questionnaires to monitor disease status, treatment effects, and quality of life. Follow-up visits will continue every 3 to 12 months for up to 15 years after study treatment ends to track long-term outcomes. Researchers will measure survival, symptom changes, adverse events, and minimal residual disease levels to evaluate treatment impact.

Age: 18Years +All GendersPhase 3
748 locations
M

Actively Recruiting

Researchers are studying Medicare beneficiaries with Lumbar Spinal Stenosis LSS and Neurogenic Claudication NC to compare outcomes after two different procedures MILD Percutaneous Image-Guided Lumbar Decompression and Interspinous Process Decompression IPD. This observational study tracks patients treated since January 1, 2017, evaluating the rates of surgical and minimally invasive interventions as well as any harms related to these procedures over 24 months. The study uses Medicare claims data and does not require prior patient consent or IRB oversight. The study includes two groups of patients those who received the MILD procedure, involving partial decompression under image guidance by removing tissue and bone at the affected spinal level, and those who underwent IPD, a device-based decompression technique. Both groups are observed through Medicare data for two years after their initial procedure to assess the need for further surgeries or interventions and to monitor for any complications. Participants are followed for 24 months after their index procedure using Medicare claims data. Researchers monitor the rates of harms associated with the initial treatment and the frequency of additional surgical or minimally invasive interventions. Since this is an observational study, data collection relies on existing Medicare records without direct patient involvement, and the study will continue enrolling patients until the sponsor stops it.

Age: 18Years +All Genders
2393 locations
E

Actively Recruiting

Researchers are evaluating the addition of pembrolizumab, a type of immunotherapy, to standard chemotherapy for patients with stage IIA, IIB, IIIA, or IIIB non-small cell lung cancer NSCLC that has been completely removed by surgery. This phase III trial aims to compare disease-free survival and overall survival between different treatment approaches, including chemotherapy alone and chemotherapy combined with pembrolizumab. The study also investigates side effects, drug discontinuation rates, quality of life, and specific biomarkers such as PD-L1 expression and tumor mutational burden. Participants are randomly assigned to one of two treatment groups. Both groups initially receive one of four chemotherapy regimens every 21 days for four cycles, chosen by their doctor. In one group, pembrolizumab is given after chemotherapy as an intravenous infusion every 21 days for up to 17 cycles or every 6 weeks for up to 16 cycles. In the other group, pembrolizumab is given together with chemotherapy during the initial cycles and then continued as monotherapy. Patients undergo various scans and blood tests throughout the study, including echocardiograms, MRIs, CT scans, and blood sample collections. During the trial, participants are closely monitored for disease status and side effects. Follow-up visits occur six weeks after treatment, then every three months for two years, every six months for years two to four, and annually for up to ten years after randomization. Quality of life questionnaires and symptom assessments are also completed. The main measure of success is disease-free survival, tracked for up to five years after enrollment. Safety and overall survival are reviewed for up to ten years to ensure long-term monitoring.

Age: 18Years +All GendersPhase 3
1151 locations
C

Actively Recruiting

Healthy Volunteer

This trial studies parents or caregivers grieving the traumatic or unexpected death of a child under 25 years old. It compares two approaches to support these bereaved parents after their loss, addressing a gap in medical examiner or coroner ME services who often have limited training in helping grieving families. The goal is to find effective ways to connect parents to grief resources and improve their mental and physical health during this difficult time. Participants are randomly assigned to one of two interventions managed by Missing Pieces, a community-based organization helping families find grief support. The first intervention, CommunityRx-Bereavement CRx-B, offers personalized support with a Grief Navigator who contacts parents by phone or text, provides tailored grief resources, and maintains contact over 12 months. The second intervention, General Bereavement Support Information GBSI, sends parents general grief resource links via unidirectional text messages at multiple times after the childs death. Parents complete surveys about 6.5 months after their childs death to evaluate outcomes like their confidence in finding resources and experiences of complicated grief. The study monitors how well these interventions support parents over time, with the trial running from 2024 to early 2028. Participants are involved through referrals from medical examiners or coroners and ongoing communication from Missing Pieces, aiming to improve bereavement care systems.

Age: 18Years +All GendersPhase Not Applicable
7 locations